Study: NCT06349044

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin and Capecitabine
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Capecitabine
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin and Capecitabine
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Capecitabine
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-VEGF 15mg/kg
Description: Bevacizumab 15mg/kg d1 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF 15mg/kg
Description: Bevacizumab 15mg/kg d1 iv q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-VEGF 7.5mg/kg
Description: Bevacizumab 7.5mg/kg d1 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF 7.5mg/kg
Description: Bevacizumab 7.5mg/kg d1 iv q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine and Cisplatin
Description: Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w